fungal infections
Drug-Resistant Candida auris Has a Health Equity Component
With Candida auris cases surging by more than 200% between 2019 and 2021 in the United States, this emerging ...
NOVEMBER 21, 2024
Cresemba Granted Pediatric Indication for Invasive Aspergillosis and Mycormycosis
The FDA expanded the indication for Cresemba, an azole antifungal, to treat invasive aspergillosis and mucormycosis ...
DECEMBER 12, 2023
Echinocandin Resistant C. auris Tripled in 2021
The number of Candida auris infections resistant to echinocandins, which has spread at an alarming rate ...
MARCH 27, 2023
FDA Approves Rezzayo, a Novel Echinocandin
Rezzayo, a novel echinocandin, is indicated for the treatment of candidemia and invasive candidiasis in adults 18.
MARCH 23, 2023
New Entries Represent an ‘Exciting Time’ for Antifungal Rx
Invasive fungal infections represent a growing threat to transplant patients and other vulnerable populations, but ...
FEBRUARY 14, 2023
Rezafungin Receives Nod From FDA Antimicrobial Drugs Advisory Committee
In a 14-0 vote, the FDA’s Antimicrobial Drugs Advisory Committee recommended approval for rezafungin (Cidara ...
JANUARY 29, 2023
Pan-Resistant C. auris Identified in U.S.
With only three classes of antifungals available, treatment options for C. auris infections are limited. Widespread ...
SEPTEMBER 28, 2021
COVID-19–Associated Aspergillosis: A New Threat
COVID-19–associated invasive pulmonary aspergillosis (CAPA) is a new entity affecting critically ill COVID-19 ...
NOVEMBER 23, 2020
Rehab Expert: Pain Patients Denied Needed Opioids in Palliative Care
There is a gap between state and federal health care laws and treatment protocols for those with chronic pain ...
DECEMBER 26, 2017
Invasive Fungal infections Demand Early Action
Antifungals differ in their spectrum of activity, so matching the right drug with the right organism helps combat ...
JUNE 30, 2016